 comparison ribavirin placebo cdc group iii human immunodefici viru infect spanish ribavirin trial group efficaci safeti ribavirin patient human immunodefici viru hiv infect multicentr placebo-control trial cdc group iii hiv-infect individu februari octob treatment time week individu treatment group similar baselin subject intraven drug abus main risk factor hiv infect ribavirin dose mg/kg mouth averag dose mg patient placebo group cdc group iva ribavirin group progress group differ signific signific differ cell count total lymphocyt total white cell ratio group treatment import side-effect